Capital strategy to deliver on key value building initiatives Innate Immunotherapeutics has announced a two-stage capital raising to fund ongoing clinical efficacy trials and development of its proprietary MIS416 drug. Stage 1 involves a private placement of 10M shares at A$0.25/share to US investors Stage 2 is a 1 for 9 Non-Renounceable Rights Issue […]